These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26980172)

  • 41. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
    Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Capecitabine-Related Neurotoxicity Presenting as Oromandibular Dystonia.
    Cengiz A; Aybay MN; Sarıcı SF; Öner V; Arslan FZ; Cengiz A
    J Oncol Pract; 2018 Mar; 14(3):202-204. PubMed ID: 29303645
    [No Abstract]   [Full Text] [Related]  

  • 44. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Actinic keratosis and capecitabine therapy.
    Higa GM; Kovach RF; Abraham J
    J Oncol Pharm Pract; 2005 Dec; 11(4):151-3. PubMed ID: 16595067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiation recall myelitis following capecitabine: First case report.
    Guerreiro C; Albuquerque L; Reimão S
    Clin Neurol Neurosurg; 2020 Sep; 196():105978. PubMed ID: 32540712
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
    Seruga B; Tannock IF
    J Clin Oncol; 2008 Jun; 26(18):2940-2. PubMed ID: 18458041
    [No Abstract]   [Full Text] [Related]  

  • 52. Atypical cutaneous vasculitis under lapatinib.
    Peuvrel L; Quereux G; Brocard A; Saint-Jean M; Freour E; Josselin N; Audouin AF; El Kouri C; Dreno B
    Eur J Dermatol; 2013; 23(4):540-1. PubMed ID: 23965414
    [No Abstract]   [Full Text] [Related]  

  • 53. Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
    Tariq Z; Mudge R; Phillips S
    Am J Ther; 2018; 25(6):e742-e743. PubMed ID: 29889674
    [No Abstract]   [Full Text] [Related]  

  • 54. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer.
    Celik E; Samanci NS; Karadag M; Demirci NS; Demirelli FH; Ozguroglu M
    Med Oncol; 2021 Jan; 38(1):11. PubMed ID: 33452614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H; Azim HA
    Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
    Takeda M; Okamoto I; Fukuoka M; Nakagawa K
    J Clin Oncol; 2010 Jun; 28(17):e273-4. PubMed ID: 20385983
    [No Abstract]   [Full Text] [Related]  

  • 57. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
    Zurayk M; Keung YK; Yu D; Hu EH
    J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
    Kodali S; Bathini V; Rava P; Tipirneni E
    J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
    [No Abstract]   [Full Text] [Related]  

  • 59. Severe palmar-plantar erythema in a patient with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.
    Damasiewicz MJ; Chionh FJ; Hayes T
    Intern Med J; 2007 Jul; 37(7):505-6. PubMed ID: 17547732
    [No Abstract]   [Full Text] [Related]  

  • 60. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.